A two-year runway before tariffs hit sounds like plenty of time. It isn’t, and if you’re a generic drug manufacturer, API supplier, or distributor reading the fine print, you already know the real work starts this year, not in 2028. The financing question isn’t about the tariff itself. It’s about how you fund inventory builds, new supplier qualification, and domestic capacity ahead of a deadline that will not move for anyone’s cash flow calendar.
What happened
The administration announced plans to impose tariffs on generic drugs starting in 2028, with a two-year delay built in specifically to give companies time to shift production toward U.S. soil, according to CNBC’s coverage of the policy. The goal is straightforward: reduce reliance on low-cost overseas producers, India chief among them, and rebuild domestic generic manufacturing. The problem is also straightforward. India supplies something like 40 percent of generic drugs sold in the U.S. by volume, and that share exists because Indian manufacturers can produce at a cost structure American plants have not matched in decades. A tariff doesn’t change that cost structure. It just adds a tax on top of it, or forces a scramble to build alternatives.
Two years of lead time is a policy compromise, not an operational one. Qualifying a new API supplier, retrofitting or building a domestic facility, and getting FDA sign-off on a changed manufacturing process routinely takes three to five years in this industry. Companies that wait until 2027 to start moving will be caught flat-footed. Companies that move now will spend cash they don’t have sitting idle waiting for revenue that’s still years out.
What it means for generic drug cash flow
This is a working capital problem dressed up as a trade policy story. Three things are happening at once, and each one eats cash differently:
- Inventory front-loading. Smart operators will build safety stock of tariff-affected inputs before 2028, locking in current pricing before the tax hits. That means bigger purchase orders, longer payment terms with overseas suppliers, and cash tied up in warehouses instead of available for payroll or R&D.
- Domestic capacity investment. Building or retrofitting a U.S. plant to produce generics that currently come from India or China is a multi-year, multi-million-dollar bet. Very few generic manufacturers, especially the mid-size ones that make up most of the industry, have that kind of capital sitting on the balance sheet.
- Margin compression during the transition. Generics already run thin margins, often in the single digits. Any added cost, whether it’s tariffs, dual-sourcing premiums, or new facility overhead, gets absorbed somewhere. Distributors and pharmacies will push back on price increases, which means manufacturers eat the difference until volume catches up.
None of this is unique to pharma. We’ve seen the same dynamic play out with importers squeezed by cross-border cost gaps and manufacturers dealing with rising input costs with no clean way to pass them through. Trade policy changes the cost side of the ledger long before it changes the revenue side, and companies that don’t plan for that gap run out of cash waiting for the policy to “settle.”
How the right financing fits
For a generic manufacturer or API distributor bridging this transition, purchase order financing is the tool that matches the problem. If you’ve landed a contract with a hospital system, PBM, or wholesaler and need to fund a large inventory buy or a supplier deposit before you can invoice, PO financing covers that gap without requiring you to already have the cash on hand. It’s built for exactly this scenario: a confirmed order, a real supplier cost, and a timing mismatch between when you pay and when you get paid.
If your challenge is more about slow-paying customers, hospital networks and large distributors that stretch payment terms to 60 or 90 days, invoice factoring solves a different piece of the same puzzle. You get paid on invoices you’ve already issued instead of waiting out the payment cycle, which keeps daily operations funded while you’re also trying to invest in longer-term sourcing changes. Our invoice factoring guide breaks down how the mechanics work if you haven’t used it before, and our piece on what factoring actually costs is worth reading before you assume it’s more expensive than it is.
For companies actually building or retrofitting domestic capacity, equipment financing is the more direct fit since it funds the machinery itself rather than the invoices around it, preserving your working capital for inventory and payroll separately.
What to do this week
- Map every SKU that depends on Indian or Chinese API sourcing and estimate the tariff exposure per unit if nothing changes by 2028.
- Talk to your existing suppliers now about locking in multi-year pricing before the transition window narrows and everyone else is negotiating at the same time.
- Get a real cost estimate for domestic capacity, whether that’s a new line, a retrofit, or a contract manufacturer relationship, so you’re not guessing at the capital need in 2026.
- Review your current receivables aging. If hospital systems or distributors are already stretching you past 60 days, that’s a cash flow problem today, independent of any tariff.
- Line up a financing partner before you need one. Underwriting takes time, and you don’t want to be shopping for capital the same month a supplier deposit comes due.
This isn’t a one-time capital raise problem. It’s a multi-year cash flow management problem, and it rewards companies that start planning in year one, not year three. We’ve written before about how factoring can fund growth without piling on debt, and that logic applies directly here: you don’t want to leverage the balance sheet just to survive a policy transition you saw coming.
FAQ
Does the 2028 tariff timeline mean generic drug companies can wait to act?
No. Supplier requalification, FDA approval for manufacturing changes, and domestic facility buildout routinely take three to five years. Waiting until the tariff is close to taking effect leaves no room to actually reshore production before it hits.
Will tariffs raise generic drug prices for consumers?
Some cost will likely pass through, but generics operate on thin margins and heavy pricing pressure from PBMs and distributors, so manufacturers will absorb a meaningful share of the increase, at least in the short term.
What financing option works best for a generic manufacturer building domestic supply?
It depends on the specific gap. Purchase order financing fits large inventory buys or supplier deposits tied to confirmed orders. Invoice factoring fits slow-paying receivables from hospitals or distributors. Equipment financing fits new domestic production lines. Rates, advance amounts, and approval all vary by credit profile, are subject to underwriting, and are not guaranteed.
How fast can a company access financing to prepare for this transition?
Timelines vary by lender, documentation, and credit profile. Factoring and PO financing are generally faster to fund than a traditional bank term loan, but exact speed is subject to underwriting and not guaranteed.
This article is for general informational and educational purposes only and does not constitute financial, legal, tax, or investment advice. Factoring terms vary by business, credit profile, and industry, and nothing here is an offer or guarantee of funding, rates, or approval. Consult a qualified professional before making financial decisions.
Tired of waiting to get paid? See what Factor & Fund can do for a business like yours. Apply in minutes. Approval and terms are subject to underwriting, and no outcome is guaranteed.